ArticleFrontiers in neurology
Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms of Acupuncture on the Neurovascular Unit in Migraine: A Narrative Review.European journal of neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Long-term real-world evidence beyond 24 months for anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies is scarce, particularly regarding treatment persistence and planned discontinuation after goal attainment. Methods: We conducted a single-center retrospective study of consecutive patients aged ≥15 years who initiated galcanezumab or fremanezumab (monthly/quarterly) between May 2021 and June 2022. Specifically, patients aged ≥15 years with episodic migraine (EM; <15 headache days/month), high-frequency EM (HFEM; 8-14 days/month), or chronic migraine (CM; ≥15 days/month) were included according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria. The outcomes included monthly migraine days (MMDs), the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test (HIT-6), and the Visual Analogue Scale (VAS), which were assessed at baseline and at 1, 3, 6, 12, and 36 months. Responder rates (RRs) (≥50%, ≥75, and 100%) and continuation/discontinuation reasons were summarized with prespecified and sensitivity analyses. The primary subgroup analysis was prespecified as EM vs. HFEM+CM. Results: Overall, 50 patients were analyzed at baseline (mean age: 42.5 years; 88% women); 28 of the 50 (56%) patients continued therapy for 3 years. Among patients who continued therapy, MMDs decreased from 12.0 ± 5.4 to 5.6 ± 5.4 at 36 months, with parallel improvements in the MIDAS, HIT-6, and VAS (all Conclusion: Over 3 years, anti-CGRP monoclonal antibodies provided sustained preventive effectiveness and favorable tolerability in routine practice, supporting individualized decision-making regarding continuation, planned discontinuation, and regimen selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.